George D Maynard Selected Research

N,N- bis(1,3- benzodioxol- 5- ylmethyl)- 1- butyl- 2,4- diphenyl- 1H- imidazole- 5- methanamine

12/2008

Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George D Maynard Research Topics

Disease

1	Spinal Cord Injuries (Spinal Cord Injury) 01/2020
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 01/2019
1	Alzheimer Disease (Alzheimer's Disease) 01/2019
1	Scrapie 01/2019
1	Hypersensitivity (Allergy) 01/2013
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 09/2012
1	Wounds and Injuries (Trauma) 09/2012
1	Neutropenia 12/2008
1	Obesity 06/2008

Drug/Important Bio-Agent (IBA)

1	Indicators and Reagents (Reagents)IBA 01/2020
1	LigandsIBA 01/2020
1	Nogo ReceptorsIBA 01/2020
1	Prion ProteinsIBA 01/2019
1	Amyloid (Amyloid Fibrils)IBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	N- (1- ethylpropyl)- (3- methoxy- 5- (2- methoxy- 4- trifluoromethoxyphenyl)- 6- methyl- pyrazin- 2- yl)amineIBA 01/2013
1	5- (6- isopropyl- 2- methylaminopyridin- 3- yl)- (N- (1- ethyl)propyl)- 3- methoxy- 6- methylpyrazine- 2- amineIBA 01/2013
1	Pharmaceutical PreparationsIBA 09/2012
1	N,N- bis(1,3- benzodioxol- 5- ylmethyl)- 1- butyl- 2,4- diphenyl- 1H- imidazole- 5- methanamineIBA 12/2008
1	RimonabantIBA 06/2008

Therapy/Procedure

1	Therapeutics 09/2012